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ABSTRACT 
Immune thrombocytopenia (ITP) is a rare but well-recognized post-allogeneic hematopoietic stem cell 
transplant (HSCT) autoimmune complication for which a standard treatment approach is lacking. Herein we 
report on an adult patient affected by high-risk acute myeloid leukemia (AML) who developed a post-HSCT ITP. 
Due to the refractoriness to first-line therapies the patient underwent the thrombopoietin (TPO) mimetic 
Eltrombopag obtaining the ITP resolution. We also discuss the clinical course of ITP in post-HSCT setting and 
pros and cons of different therapeutic strategies, focusing on the emerging role of TPO mimetics.  
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Introduction 
 Hematological autoimmune complications can 
occur, although infrequently, after autologous and 
allogeneic hematopoietic stem cell transplantation 
(HSCT). Immune thrombocytopenia (ITP) is a rare but 
well recognized post-autologous HSCT complication, 
whose underlying pathogenetic mechanisms include 
imbalances in CD4/CD8 T cell subsets, abnormal 
expression of self antigens as a result of damage 
induced by radiotherapy or chemotherapy, and viral 
infections that can occur during the post-transplant 
period1. After allogeneic HSCT, isolated thrombocytope-
nia can result from poor (or loss of) engraftment, 
infectious events, graft versus host disease (GVHD), 
impending relapse of the underlying hematologic disease 
or, in the absence of any of these conditions, immune 
dysregulation. To our knowledge, there are few data 
about the incidence of post-allogeneic HSCT ITP 
because they are usually described in case reports or 
brief case series whereas large clinical studies often 
include other types of post-HSCT thrombocytopenia. 
Indeed post-allogeneic HSCT ITP pathogenesis is far 
from been elucidated and a consensus for treatment 
lacks too2. In fact first line therapies such as steroid and 
intravenous gamma globulins (IVIG) tend to be 
ineffective in most cases2, whereas second line 
treatments may prove more toxic than we observe in 
general ITP population. Thrombopoietin (TPO) mimetic 
agents Romiplostim and Eltrombopag have recently 
appeared in the landscape of ITP treatment but their 
efficacy and safety in post transplantation setting have 
not been extensively evaluated yet6-12. Herein we 
describe the clinical course of an adult patient affected 
by post-allogeneic HSCT ITP refractory to prednisolone, 
IVIG and Rituximab who was treated with Eltrombopag 
because of the high risk of side effects associated with 
other second line therapies.  
Case Report 
 In December 2013 a 55-years old man was 
diagnosed with de novo FLT3-ITD and NPM1-mutated 
acute myelogenous leukaemia (AML), FAB M5a. Between 
December 2013 and April 2014 the patient received 
standard induction chemotherapy with cytarabine, 
etoposide and mitoxantrone, obtaining complete 
remission, and two consolidation cycles with high-dose 
cytarabine. Because of the high biological risk of the 
disease, in June 2014 the patient underwent an HSCT 
from an HLA-matched unrelated donor. The myeloabla-
tive conditioning included cyclophosphamide and total 
body irradiation, while GVHD prophylaxis consisted of 
short-course methotrexate and cyclosporine. The 
immediate post-transplantation course was unremarka-
ble, and no infectious complications or GVHD were 
observed. The engraftment was obtained on day 15, and 
a full-donor chimerism was documented on day 21; 
cyclosporine was gradually tapered off and discontinued 
by day 185.  
 In January 2015, on day 230 after HSCT, the 
patient developed bilateral lower limb petechiae. At that 
time the platelet count was 8000/μl, whereas haemoglo-
bin levels and white blood cell count remained within the 
normal range. Platelet transfusions were no effective. A 
bone marrow aspirate revealed a normocellular marrow 
with 2-3 megacaryocytes per low-magnification field 
without dysplastic aspects. No cytomegalovirus, Epstein-
Barr virus, and herpes simplex virus 1-2-6-8 DNA copies 
were detected in bone marrow. A full-donor chimerism 
was confirmed.  
 A diagnosis of ITP was therefore made. The 
patient was initially treated with IVIG at the dosage of 
0.4 g/Kg for 5 days without success; oral prednisone (1 
mg/Kg per day) was then administered for 3 weeks with 
no results. Given the high surgical (the platelet count 
never rose above 10 000/ml) and infectious risks of 
splenectomy, in March 2015 the patient underwent a 
further pharmacological treatment (Rituximab 375 mg/
sqm for four-weekly doses) without any improvement in 
platelet count. Although data about the post-HSCT use 
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of TPO-receptor agonists were scanty, starting from May 
2015 the patient received Eltrombopag 50 mg per day, 
escalated to 75 mg per day 2 weeks later. After 6 weeks 
of treatment the platelet count rose stably above 10 
000/ml reaching 50 000/μl after 3 months (Figure 1); 
the treatment was well tolerated and caused just a 
grade 1 transaminitis. Unfortunately, in October 2015, 5 
months after Eltrombopag beginning and 16 months 
after HSCT, the patient developed red-purplish skin 
nodules; punch biopsy taken from a left arm skin lesion 
confirmed AML relapse. At that time bone marrow 
examination showed no increase in blast cells, however 
one month later a bone marrow relapse also occurred 
and the patient died of septic shock during reinduction 
chemotherapy.  
 
Discussion 
 ITP is a rare but well-recognized post-HSCT 
hematologic autoimmune complication. Although 
reduced conditioning regimens and matched unrelated 
donors have been suggested as risk factors2, donor 
haematological background should also be considered. 
Indeed ITP transmission from donor to recipient, 
especially in T-replete transplantation platforms, has 
been previously described3.  
 As occurred in our case and according to the 
literature, post-HSCT ITP is frequently refractory to first 
line therapies such as steroids and IVIG2 thus represent-
ing a clinical challenge. Different strategies have been 
reported to manage refractory post-HSCT ITP (Table 1). 
Gergis U et al treated successfully a refractory post-
HSCT ITP patient resuming immunosuppression with 
tacrolimus, which had been tapered off and stopped 3 
months before4. Although the patient obtained prompt 
platelet recovery, this approach may not be advisable in 
some malignant disease, such as high-risk AML, in which 
prolonged immunosuppression may reduce 
graft versus leukaemia effect and increase 
relapse risk. Splenectomy was reported as 
a treatment option for severe post-
transplant hematologic autoimmune 
diseases, but serious infectious complica-
tions are a major concern and limit its use 
in this setting5. Rituximab was also 
reported as an effective treatment for post
-HSCT ITP. Raj K et al treated successfully 
two post-HSCT ITP patients with Rituximab 
without significant toxicity2; Faraci M et al 
demonstrated that Rituximab is a good 
option for children affected by post-HSCT 
hematologic autoimmune complications, 
but among 10 post-HSCT ITP patients only 
3 received Rituximab, with 2 of them 
showing a successful response6. As for our case we 
cannot completely exclude that a delayed effect of 
Rituximab contributed to the response. 
 The TPO mimetics Romiplostim and Eltrom-
bopag are now widely used in relapsed/refractory ITP 
patients, with a response rate from 60% to 90%7,8, as 
well as in other conditions such as aplastic anemia and 
chronic HCV infection, but their use in the post-HSCT 
Figure 1. Course of platelet count and its correlation with therapeuti-
cal interventions and days after transplantation.   
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setting is not extensively investigated yet. In addition 
most studies include post-HSCT ITP along with post-
HSCT thrombocytopenia secondary to other causes. 
Therefore prospective studies specifically focused on 
post-HSCT ITP are lacking. Poon LM et al reported 3 
cases of severe post-HSCT thrombocytopenia (1 post-
HSCT ITP and 2 thrombocytopenias secondary to graft 
failure) successfully treated with Romiplostim. Worthy of 
note those patients did not relapse of their haematologi-
cal disease nor developed marrow fibrosis9. Other 
groups argue in favour of using Romiplostim in post-
transplant setting, both in children and adults10,11. 
However, if we consider that Romiplostim is reported to 
increase the leukemic evolution of patients affected by 
myelodisplastic syndromes12, there may be a concern in 
its use in patients with underlying high risk myeloid 
malignancy, as in our case.  
 Eltrombopag is a nonpeptide orally active TPO-
receptor agonist. A series of 12 patients affected by post
-transplant immune or not immune thrombocytopenia 
treated with Eltrombopag has been recently reported by 
Tanaka T et al13; the response rate was 72%, with no 
significant increase in risk of marrow fibrosis, disease 
relapse or worsening of pre-existing GVHD. In vitro and 
in vivo studies show conflicting results about the direct 
effects of Eltrombopag on AML cells and on stromal 
supportive microenvironment14,15, thus making this topic 
an interesting research area. Although in our case 
disease relapse occurred 5 months after Eltrombopag 
beginning, it seems more likely that it was favoured by 
the high biological risk of FLT3-ITD AML rather than by 
the Eltrombopag possible stimulating effect on 
leukaemia cells. Moreover, we assumed that the risk of 
fatal bleeding exceeded the risk of leukaemia relapse. 
Anyway, caution is advisable in using Eltrombopag in 
this specific setting until more data will be available and 
strategies to reduce bone marrow exposure to this agent 
– such as using it as a bridge to splenectomy or other 
treatment platforms – could be investigated in the near 
future. 
 In summary we present a case of refractory post
-allogeneic HSCT ITP - not associated with GVHD or 
infectious events - successfully treated with Eltrom-
bopag. According to our experience TPO-mimetics could 
represent a reasonable treatment option in HSCT 
patients. However prospective studies are needed in 
order to evaluate their efficacy and safety in HSCT 
settings. 
 
Author 
No. Refractory 
Post-HSCT ITP 
patients Treatment 
Platelet 
recovery 
>50.000/mmc 
Follow-up 
(months) Toxicity Reference 
Gergis 1 Tacrolimus 1/1 2 no 4 
Proleznik 2 Splenectomy 2/2 12 
1 patient died 
of septic shock 5 
Raj 2 Rituximab 2/2 6-13 no 2 
Faraci 6 
Rituximab (3 out 
of 6 patients) 2/3 34-43  no 6 
Poon 1 Romiplostim 1/1 24 no 9 
Beck 1 Romiplostim 1/1 2 no 10 
Battipaglia* 3 Romiplostim 3/3 5-10 no 11 
Tanaka* 7 Eltrombopag 6/7 2-8 no 13 
Table 1. Treatment of refractory post-allogeneic HSCT ITP  
* Patients included in these studies had post-transplant thrombocytopenia defined as secondary 
failure of platelet recovery (SFPR).  
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